anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Immix Biopharma · pitchdeck

Immix Biopharma | Investor Presentation Deck | 52 slides

52 pages · 5 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Immix Biopharma | Investor Presentation Deck | 52 slides

Immix Biopharma · 2023-08
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 30 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 6 slides 100% 6/6 slides 100% 6/6 slides · 28 hits
— 0/6 slides
66.7% 4/6 slides 66.7% 4/6 slides 100% 6/6 slides · 12 hits 16.7% 1/6 slides Solution 14 slides 100% 14/14 slides 100% 14/14 slides · 70 hits
— 0/14 slides
7.1% 1/14 slides 64.3% 9/14 slides 100% 14/14 slides 35.7% 5/14 slides Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 11 hits
— 0/2 slides
50% 1/2 slides
— 0/2 slides
100% 2/2 slides · 5 hits
— 0/2 slides
Competition 4 slides 100% 4/4 slides 100% 4/4 slides · 18 hits
— 0/4 slides
100% 4/4 slides 75% 3/4 slides 100% 4/4 slides · 9 hits
— 0/4 slides
Team 4 slides 100% 4/4 slides 100% 4/4 slides · 24 hits
— 0/4 slides
— 0/4 slides
— 0/4 slides
100% 4/4 slides
— 0/4 slides

Slide inventory

52
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a numbered list format to present key value propositions.summarize
Open slide detail
04
The slide uses a wave-like visual to represent market segments and their associated financial opportunities.size_opportunity
Open slide detailBeat · Problem
05
The slide highlights NXC-201's superior efficacy (100% response rate) and safety profile (zero neurotoxicity) compared to existing therapies.compare_peers
Open slide detailBeat · Problem
06
The slide explicitly notes that these are cross-trial comparisons and not head-to-head studies.compare_peers
Open slide detailBeat · Problem
07
The slide uses a table structure to contrast standard of care with the company's target segment. The bottom section uses bar charts to imply relative patient pocompare_peers
Open slide detailBeat · Problem
08
The slide explicitly warns about cross-trial comparison limitations in the footer.compare_peers
Open slide detailBeat · Problem
09
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.frame_problem
Open slide detailBeat · ProblemLoop · Cost Of Inaction
10
Includes a cartoon liver character at the bottom.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
Includes a footer citing FDA approval precedents for similar patient population sizes.plan_implementation
Open slide detailBeat · Solution
12
Includes detailed clinical trial citations in the footer.show_traction
Open slide detailBeat · Solution
13
The slide uses a standard pharmaceutical pipeline table format.show_traction
Open slide detailBeat · Solution
14
The slide uses a two-column layout to track progress for two distinct drug programs.plan_implementation
Open slide detailBeat · Solution
15
The slide uses a side-by-side comparison of two proprietary platforms.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
16
transition
Open slide detailBeat · SolutionLoop · Golden Circle
17
Includes comparative charts for transduction efficiency and anti-exhaustion capability.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
18
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs competitors.argue_timing
Open slide detailBeat · SolutionLoop · Golden Circle
19
transition
Open slide detailBeat · Solution
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.compare_peers
Open slide detailBeat · Solution
21
Includes detailed source citations and disclaimer regarding cross-trial comparisons.compare_peers
Open slide detailBeat · Solution
22
The slide uses a comparison table framework to highlight NXC-201's competitive advantage in safety (lower ICANS/CRS) and efficacy (higher ORR/CR).compare_peers
Open slide detailBeat · Solution
23
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.show_traction
Open slide detailBeat · Solution
24
The chart demonstrates deepening clinical responses over time, with sCR/CR increasing from 50% to 83%.show_traction
Open slide detail
25
The table highlights clinical safety data for NXC-201, showing low incidence of severe adverse events.analyze_data
Open slide detail
26
The slide highlights specific safety metrics for two dosage groups (100x10^6 and 300x10^6 cells).compare_peers
Open slide detail
27
Includes a footer citing FDA approval precedents for patient population sizes.plan_implementation
Open slide detail
28
The diagram illustrates a standard 3+3 or similar dose escalation design.plan_implementation
Open slide detail
29
The slide features a scientific illustration of cellular structures, likely representing the drug delivery mechanism.transition
Open slide detail
30
Includes a complex biological pathway diagram and three distinct data visualizations (line chart, scatter plot, bar chart) supporting the efficacy claims.present_solution
Open slide detail
31
The slide uses bar charts to compare IMX-110 performance against standard drugs like Trabectedin and a 4-drug combination.show_traction
Open slide detail
32
Includes a scientific mechanism of action diagram showing iMX-110 effects on tumor microenvironment.show_traction
Open slide detail
33
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor regression.show_traction
Open slide detail
34
transition
Open slide detail
35
Includes waterfall charts and longitudinal patient response plots; highlights PFS (progression-free survival) and line of therapy.show_traction
Open slide detail
36
The slide uses a bubble chart to map mPFS against patient treatment history and a table to detail clinical outcomes across lines of therapy.frame_problem
Open slide detail
37
The chart visualizes a single data point (4 months mPFS at 100% pre-treated status) while the table provides detailed clinical trial outcomes.show_traction
Open slide detail
38
The slide uses a process flow diagram to show the progression of clinical trials for two different treatment regimens.plan_implementation
Open slide detail
39
transition
Open slide detail
40
The slide uses a process-flow style layout to connect platform capabilities to specific clinical assets.present_solution
Open slide detail
41
The slide uses a 3-pillar framework to explain the platform, followed by a product-specific breakdown.present_solution
Open slide detail
42
Includes technical diagrams of the drug construct, comparative histology, and survival curves.present_solution
Open slide detail
43
Includes two sets of charts: tumor volume line graphs and survival curves. References specific study methodology in footnotes.show_traction
Open slide detail
44
The slide uses a two-part structure: clinical efficacy (top right) and mechanism of action (bottom right).present_solution
Open slide detail
45
transition
Open slide detailBeat · Team
46
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board Members (bottom).other
Open slide detailBeat · Team
47
other
Open slide detailBeat · Team
48
other
Open slide detailBeat · Team
49
summarize
Open slide detail
50
appendix
Open slide detail
51
The slide uses a bar chart to contrast the combined sales of two groups of drugs, illustrating the market size for specific oncology indications.size_opportunity
Open slide detail
52
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.compare_peers
Open slide detail